Meeting
2019 ASCO Annual Meeting
A real-world evidence study of CDK4/6 inhibitor treatment patterns and outcomes in metastatic breast cancer by gBRCA mutation status.
Authors
Kimmie McLaurin
AstraZeneca Pharmaceuticals, LP, Gaithersburg, MD
Kimmie McLaurin , Tapashi Dalvi , Jenna M Collins , Beth L Nordstrom , Susan McCutcheon , James C Bennett , Brian R Murphy , Puneet K Singhal , Josefa Maria Briceno
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Cancer Prevention, Hereditary Genetics, and Epidemiology
Track
Prevention, Risk Reduction, and Genetics
Sub Track
Etiology/Epidemiology
Citation
J Clin Oncol 37, 2019 (suppl; abstr 1563)
DOI
10.1200/JCO.2019.37.15_suppl.1563
Abstract #
1563
Poster Bd #
57
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase I trial of palbociclib (palbo) and bosutinib (bos) with fulvestrant (fulv) in patients (pts) with hormone receptor–positive, HER2-negative (HR+/HER2-) metastatic breast cancer (MBC) refractory to an aromatase inhibitor (AI) and a CDK4/6 inhibitor (CDK4/6i).
First Author: Candace Bavette Mainor
Poster
2023 ASCO Annual Meeting
CAPTOR-BC: Comprehensive analysis of spatial, temporal and molecular biomarkers predicting response and resistance to first-line treatment with ribociclib + ET in HR+, HER2- advanced breast cancer.
First Author: Peter A. Fasching
Poster
2023 ASCO Annual Meeting
LEONARDA-1: Phase III randomized study of lerociclib plus fulvestrant in patients with HR+, HER2- locally advanced or metastatic breast cancer that has progressed on prior endocrine therapy.
First Author: Binghe Xu
Poster
2022 ASCO Annual Meeting
CDK4/6 inhibitors outcomes in patients with advanced breast cancer based on HER2-low expression.
First Author: Laura Sabina Lapuchesky